Erratum: Peripheral Measurable Residual Disease Activity Assessment by MALDI-TOF Mass Spectrometry in Patients With Newly Diagnosed Multiple Myeloma in the Phase III GMMG-HD7 Trial

J Jia xiang Jin (1Heidelberg Myeloma Center and German-speaking Myeloma Multicenter Group (GMMG), Heidelberg University Hospital, Internal Medicine V, Hematology, Oncology and Rheumatology, Heidelberg, Germany) V Varun R. Ginde (Division of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, Germany) S Stefanie Huhn (1Heidelberg Myeloma Center and German-speaking Myeloma Multicenter Group (GMMG), Heidelberg University Hospital, Internal Medicine V, Hematology, Oncology and Rheumatology, Heidelberg, Germany) P Philipp Reichert (1Heidelberg Myeloma Center and German-speaking Myeloma Multicenter Group (GMMG), Heidelberg University Hospital, Internal Medicine V, Hematology, Oncology and Rheumatology, Heidelberg, Germany) U Uta Bertsch (1Heidelberg Myeloma Center and German-speaking Myeloma Multicenter Group (GMMG), Heidelberg University Hospital, Internal Medicine V, Hematology, Oncology and Rheumatology, Heidelberg, Germany) R Roland Fenk (4University Hospital Düsseldorf, Department of Hematology, Oncology and Clinical Immunology, Düsseldorf, Germany) B Britta Besemer (Department of Internal Medicine II, University Tübingen, Tübingen, Germany) A Amelie Boquoi (6University Hospital Essen, Department for Hematology and Stem Cell Transplantation, Essen, Germany) R Roland Schroers (18Medical Clinic II-Hematology and Oncology, Ruhr-University Bochum, Bochum, Germany) I Ivana von Metzler M Mathias Hänel (7Department III of Internal Medicine, Klinikum Chemnitz, Chemnitz, Germany) C Christoph Mann (10University Hospital Gießen and Marburg, Department for Hematology, Oncology and Immunology, Marburg, Germany) L Lisa B. Leypoldt (Department of Oncology, Hematology and BMT, University Medical Center Hamburg-Eppendorf, Hamburg, Germany) B Bernhard Heilmeier (12Hospital Barmherzige Brueder Regensburg, Clinic for Oncology and Hematology, Regensburg, Germany) C Christof Scheid (12Hospital Barmherzige Brueder Regensburg, Clinic for Oncology and Hematology, Regensburg, Germany) T Thorsten Peters-Regehr (13The Binding Site GmbH, part of Thermo Fisher Scientific, Schwetzingen, Germany) I Igor W. Blau C Carsten Müller-Tidow S Steffen Luntz (15Coordination Centre for Clinical Trials (KKS) Heidelberg, Heidelberg, Germany) T Tobias A.W. Holderried (16University Hospital Bonn, Department of Hematology, Oncology, Stem Cell Transplantation, Immune and Cell Therapy, Clinical Immunology and Rheumatology, Bonn, Germany) K Karolin Trautmann-Grill (3Department of Medicine I, Faculty of Medicine and University Hospital Carl Gustav Carus, Dresden University of Technology, Dresden, Germany) D Deniz Gezer (18RWTH Aachen University, Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Faculty of Medicine, Aachen, Germany) M Maika Klaiber-Hakimi (19Marien Hospital Düsseldorf, Clinic for Hematology, Oncology and Palliative Care, Düsseldorf, Germany) M Martin Müller E Evgenii Shumilov (1University Hospital Muenster, Department of Medicine A, Hematology, Oncology and Pneumology, Muenster, Germany) W Wolfgang Knauf (28Centrum für Hämatologie und Onkologie Bethanien, Frankfurt am Main, Germany) C Christian S. Michel (1Department of Hematology and Oncology, Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany) T Thomas Geer (24Diakoneo Clinic Schwäbisch-Hall, Department of Internal Medicine III, Schwäbisch-Hall, Germany) H Hendrik Riesenberg (25Hematology/Oncology Center, Bielefeld, Germany) C Christoph Lutz M Marc S. Raab N Niels Weinhold M Martin Hoffmann A Axel Benner P Peter Findeisen (28MVZ Labor Dr. Limbach und Kollegen, Heidelberg, Germany) K Katja C. Weisel H Hans J. Salwender (20Asklepios Tumorzentrum Hamburg, AK Altona and AK St. Georg, Hamburg, Germany) E Elias K. Mai H Hartmut Goldschmidt (Internal Medicine V, Hematology, Oncology and Rheumatology, German-Speaking Myeloma Multicenter Group Study Group, Heidelberg University Hospital and National Center for Tumor Diseases, Heidelberg, Germany)

Article Details

Volume / Issue Vol. 44, Issue 20
Published July 10, 2026
Pages 1955-1955
ISSN 0732-183X
Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins

ISSN: 0732-183X Health Sciences

Authors (39)

J

Jia xiang Jin

1Heidelberg Myeloma Center and German-speaking Myeloma Multicenter Group (GMMG), Heidelberg University Hospital, Internal Medicine V, Hematology, Oncology and Rheumatology, Heidelberg, Germany

V

Varun R. Ginde

Division of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, Germany

S

Stefanie Huhn

1Heidelberg Myeloma Center and German-speaking Myeloma Multicenter Group (GMMG), Heidelberg University Hospital, Internal Medicine V, Hematology, Oncology and Rheumatology, Heidelberg, Germany

P

Philipp Reichert

1Heidelberg Myeloma Center and German-speaking Myeloma Multicenter Group (GMMG), Heidelberg University Hospital, Internal Medicine V, Hematology, Oncology and Rheumatology, Heidelberg, Germany

U

Uta Bertsch

1Heidelberg Myeloma Center and German-speaking Myeloma Multicenter Group (GMMG), Heidelberg University Hospital, Internal Medicine V, Hematology, Oncology and Rheumatology, Heidelberg, Germany

R

Roland Fenk

4University Hospital Düsseldorf, Department of Hematology, Oncology and Clinical Immunology, Düsseldorf, Germany

B

Britta Besemer

Department of Internal Medicine II, University Tübingen, Tübingen, Germany

A

Amelie Boquoi

6University Hospital Essen, Department for Hematology and Stem Cell Transplantation, Essen, Germany

R

Roland Schroers

18Medical Clinic II-Hematology and Oncology, Ruhr-University Bochum, Bochum, Germany

I

Ivana von Metzler

M

Mathias Hänel

7Department III of Internal Medicine, Klinikum Chemnitz, Chemnitz, Germany

C

Christoph Mann

10University Hospital Gießen and Marburg, Department for Hematology, Oncology and Immunology, Marburg, Germany

L

Lisa B. Leypoldt

Department of Oncology, Hematology and BMT, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

B

Bernhard Heilmeier

12Hospital Barmherzige Brueder Regensburg, Clinic for Oncology and Hematology, Regensburg, Germany

C

Christof Scheid

12Hospital Barmherzige Brueder Regensburg, Clinic for Oncology and Hematology, Regensburg, Germany

T

Thorsten Peters-Regehr

13The Binding Site GmbH, part of Thermo Fisher Scientific, Schwetzingen, Germany

I

Igor W. Blau

C

Carsten Müller-Tidow

S

Steffen Luntz

15Coordination Centre for Clinical Trials (KKS) Heidelberg, Heidelberg, Germany

T

Tobias A.W. Holderried

16University Hospital Bonn, Department of Hematology, Oncology, Stem Cell Transplantation, Immune and Cell Therapy, Clinical Immunology and Rheumatology, Bonn, Germany

K

Karolin Trautmann-Grill

3Department of Medicine I, Faculty of Medicine and University Hospital Carl Gustav Carus, Dresden University of Technology, Dresden, Germany

D

Deniz Gezer

18RWTH Aachen University, Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Faculty of Medicine, Aachen, Germany

M

Maika Klaiber-Hakimi

19Marien Hospital Düsseldorf, Clinic for Hematology, Oncology and Palliative Care, Düsseldorf, Germany

M

Martin Müller

E

Evgenii Shumilov

1University Hospital Muenster, Department of Medicine A, Hematology, Oncology and Pneumology, Muenster, Germany

W

Wolfgang Knauf

28Centrum für Hämatologie und Onkologie Bethanien, Frankfurt am Main, Germany

C

Christian S. Michel

1Department of Hematology and Oncology, Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany

T

Thomas Geer

24Diakoneo Clinic Schwäbisch-Hall, Department of Internal Medicine III, Schwäbisch-Hall, Germany

H

Hendrik Riesenberg

25Hematology/Oncology Center, Bielefeld, Germany

C

Christoph Lutz

M

Marc S. Raab

N

Niels Weinhold

M

Martin Hoffmann

A

Axel Benner

P

Peter Findeisen

28MVZ Labor Dr. Limbach und Kollegen, Heidelberg, Germany

K

Katja C. Weisel

H

Hans J. Salwender

20Asklepios Tumorzentrum Hamburg, AK Altona and AK St. Georg, Hamburg, Germany

E

Elias K. Mai

H

Hartmut Goldschmidt

Internal Medicine V, Hematology, Oncology and Rheumatology, German-Speaking Myeloma Multicenter Group Study Group, Heidelberg University Hospital and National Center for Tumor Diseases, Heidelberg, Germany